Recruiting
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
NCT07440290· Phase 2/3· Cancer Research UK· Source
Contact: Dan Palmer, Dr
Recruiting
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
NCT05770544· Phase 2/3· Cancer Research UK· Source
Contact: Dan Palmer, Dr
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400· Phase 3· BeOne Medicines· Source
Contact: BeOne Medicines
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
NCT06988475· Phase 2/3· Cancer Research UK· Source
Contact: Dan Palmer, Dr
Recruiting
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
NCT05770037· Phase 2/3· Cancer Research UK· Source
Contact: Dan Palmer, Dr
Active, not recruiting
Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma
NCT05004064· Phase 2· University College, London· Source
Recruiting
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
NCT05770102· Phase 2/3· Cancer Research UK· Source
Contact: Dan Palmer, Dr
Recruiting
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
NCT05786716· Phase 2/3· Cancer Research UK· Source
Contact: Dan Palmer, Dr
Recruiting
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
NCT05768178· Phase 2/3· Cancer Research UK· Source
Contact: Dan Palmer, Dr
Recruiting
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
NCT05722886· Phase 2/3· Cancer Research UK· Source
Contact: Dan Palmer, Dr
Recruiting
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
NCT05613023· Phase 3· Institute of Cancer Research, United Kingdom· Source
Contact: Shaun Tolan
Active, not recruiting
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843· Phase 1/2· BeOne Medicines· Source
Recruiting
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· Phase 1/2· University of Birmingham· Source
Contact: S Nasim Ali
Active, not recruiting
Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms
NCT03763253· Phase 2· Imperial College London· Source
Active, not recruiting
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer
NCT04487587· Phase 2· The Clatterbridge Cancer Centre NHS Foundation Trust· Source
Active, not recruiting
Stereotactic Body Radiotherapy for the Treatment of OPD
NCT03256981· Phase 2/3· Institute of Cancer Research, United Kingdom· Source
Recruiting
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
NCT03151629· Prostate Cancer Clinical Trials Consortium· Source
Contact: Isabel Syndikus, MD
Active, not recruiting
Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer
NCT02417662· University College, London· Source
Active, not recruiting
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
NCT04116047· Phase 3· University of Birmingham· Source
Active, not recruiting
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
NCT02170090· Phase 3· Universitätsklinikum Hamburg-Eppendorf· Source
Active, not recruiting
Prostate Advances in Comparative Evidence
NCT01584258· Phase 3· Royal Marsden NHS Foundation Trust· Source